EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Management of unspecified anxiety disorder: Expert consensus

Hitoshi Sakurai iD, Ken Inada iD, Yumi Aoki iD, Masahiro Takeshima, Kenya Ie, Morito Kise, Eriko Yoshida, Takashi Tsuboi, Hisashi Yamada, Hikaru Hori, Yasushi Inada, Eiji Shimizu und 3 weitere

Neuropsychopharmacology Reports · 2023

DOI: 10.1002/npr2.12323 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropsychopharmacology Reports, 2023. Verfasst von Hitoshi Sakurai und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Kyorin University Faculty of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Anti-Anxiety Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Labor and Welfare of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Treatment guidelines with respect to unspecified anxiety disorder have not been published. The aim of this study was to develop a consensus among field experts on the management of unspecified anxiety disorder.

Methods

Experts were asked to evaluate treatment choices based on eight clinical questions concerning unspecified anxiety disorder using a nine‐point Likert scale (1 = “disagree” to 9 = “agree”). According to the responses from 119 experts, the choices were categorized into first‐, second‐, and third‐line recommendations.

Results

Benzodiazepine anxiolytic use was not categorized as a first‐line recommendation for the primary treatment of unspecified anxiety disorder, whereas multiple nonpharmacological treatment strategies, including coping strategies (7.9 ± 1.4), psychoeducation for anxiety (7.9 ± 1.4), lifestyle changes (7.8 ± 1.5), and relaxation techniques (7.4 ± 1.8), were categorized as first‐line recommendations. Various treatment strategies were categorized as first‐line recommendations when a benzodiazepine anxiolytic drug did not improve anxiety symptoms, that is, differential diagnosis (8.2 ± 1.4), psychoeducation for anxiety (8.0 ± 1.5), coping strategies (7.8 ± 1.5), lifestyle changes (7.8 ± 1.5), relaxation techniques (7.2 ± 1.9), and switching to selective serotonin reuptake inhibitors (SSRIs) (7.0 ± 1.8). These strategies were also highly endorsed when tapering the dosage of or discontinuing benzodiazepine anxiolytic drugs. There was no first‐line recommendation regarding excusable reasons for continuing benzodiazepine anxiolytics.

Conclusions

The field experts recommend that benzodiazepine anxiolytics should not be used as a first‐line option for patients with unspecified anxiety disorder. Instead, several nonpharmacological interventions and switching to SSRIs were endorsed for the primary treatment of unspecified anxiety disorder and as alternatives to benzodiazepine anxiolytics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Anxiety AgentsHumansSelective Serotonin Reuptake InhibitorsConsensusAnxiety DisordersBenzodiazepines

Stichwörter der Autor:innen

anxiolyticsbenzodiazepineexpert consensusunspecified anxiety disorder

Substanzen

Anti-Anxiety AgentsSelective Serotonin Reuptake InhibitorsBenzodiazepines

Autor:innen und Institutionen

  • Department of Neuropsychiatry, Kyorin University Faculty of Medicine, Tokyo, Japan.
  • Department of Psychiatry, School of Medicine, Kitasato University, Kanagawa, Japan.
  • Psychiatric and Mental Health Nursing, St. Luke's International University, Tokyo, Japan.
  • Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.
  • Division of General Internal Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.
  • Division of General Internal Medicine, Department of Internal Medicine, Kawasaki Municipal Tama Hospital, Kanagawa, Japan.

ORCID-Profile: Hitoshi Sakurai, Ken Inada, Yumi Aoki, Yoshikazu Takaesu

Förderung

  • Ministry of Health, Labor and Welfare of Japan

Zitieren

APA

Sakurai, H., Inada, K., Aoki, Y., Takeshima, M., Ie, K., Kise, M., Yoshida, E., Tsuboi, T., Yamada, H., Hori, H., Inada, Y., Shimizu, E., Mishima, K., Watanabe, K., & Takaesu, Y. (2023). Management of unspecified anxiety disorder: Expert consensus. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12323

Vancouver

Sakurai H, Inada K, Aoki Y, Takeshima M, Ie K, Kise M, et al. Management of unspecified anxiety disorder: Expert consensus. Neuropsychopharmacology Reports. 2023. doi:10.1002/npr2.12323

BibTeX
@article{Sakurai2023,
  author = {Sakurai, Hitoshi and Inada, Ken and Aoki, Yumi and Takeshima, Masahiro and Ie, Kenya and Kise, Morito and Yoshida, Eriko and Tsuboi, Takashi and Yamada, Hisashi and Hori, Hikaru and Inada, Yasushi and Shimizu, Eiji and Mishima, Kazuo and Watanabe, Koichiro and Takaesu, Yoshikazu},
  title = {Management of unspecified anxiety disorder: Expert consensus},
  journal = {Neuropsychopharmacology Reports},
  year = {2023},
  doi = {10.1002/npr2.12323}
}
Kostenlos starten →